Robert Gardner
Neurology · Cape Girardeau, MONPI 1346251436
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,646 of the $33,046 with a category attached, or 71.6%. Teva Pharmaceuticals USA, Inc. accounts for 76.5% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2020 at $11,022 and has fallen 96.9% since, to $338 in 2025.
Across 269 payments — averaging $122.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$25K
- AbbVie$3K
- UCB, Inc.$750
- Biogen$496
- Medtronic$386
- Kyowa Kirin, Inc.$324
- plus $2K from 29 others
What the payments were for
- Consulting fees$1,1503%
- Speaking & faculty fees$23,64672%
- Travel & lodging$2,1837%
- Food & beverage$5,94018%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 31 | $25,270 |
| AbbVie | 43 | $3,419 |
| UCB, Inc. | 32 | $750 |
| Biogen | 15 | $496 |
| Medtronic | 5 | $386 |
| Kyowa Kirin, Inc. | 15 | $324 |
| Acadia Pharmaceuticals Inc | 13 | $273 |
| EMD Serono, Inc. | 21 | $251 |
| Novartis | 6 | $233 |
| Biohaven Pharmaceuticals, Inc. | 16 | $210 |
| Eisai Inc. | 6 | $166 |
| Supernus Pharmaceuticals, Inc. | 15 | $155 |
| Lundbeck LLC | 7 | $152 |
| Amneal Pharmaceuticals LLC | 8 | $135 |
| Neurocrine Biosciences, Inc. | 2 | $130 |
| Harmony Biosciences LLC | 1 | $111 |
| E.r. Squibb & Sons, L.L.C. | 1 | $88 |
| Ipsen Biopharmaceuticals, Inc | 4 | $60 |
| MDD US Operations, LLC | 4 | $56 |
| Amgen | 3 | $46 |
| Sanofi | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Grifols USA, LLC | 2 | $33 |
| Tanabe Pharma America, Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Zyla Life Sciences, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Adamas Pharmaceuticals, Inc. | 1 | $17 |
| Apria Healthcare LLC | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,046 in reported general payments places this provider in the 85th percentile of 381 neurology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 16 | $11,769 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cape Girardeau
- Robert GardnerCape Girardeau$171K
- David LeeCape Girardeau$22K
- William RosenfeldChesterfield$2.1M
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
- Robert NaismithSaint Louis$677K
- Daniel MattsonBridgeton$451K
- Siddharth KaulBridgeton$387K
- Barbara GreenChesterfield$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.